'Novel Shc Blockers as potential Alzheimer's Disease Therapeutics
“新型 Shc 阻滞剂作为潜在的阿尔茨海默病治疗药物
基本信息
- 批准号:10611613
- 负责人:
- 金额:$ 32.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-30 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAddressAdultAffectAlzheimer&aposs DiseaseAlzheimer&aposs disease therapeuticAmericanAmyloid beta-ProteinBiological AssayBloodBrainChemicalsClinical PharmacologyDementiaDisease ProgressionGeneticHumanLeadMaximum Tolerated DoseMemoryMusNerve DegenerationNeurofibrillary TanglesNeuronsOxidative StressPenetrancePeripheral Blood Mononuclear CellPharmaceutical PreparationsProteinsResistanceSymptomsTestingage relatedapolipoprotein E-4cerebrovascularcognitive functionefficacy studyexperimental studyin vivoinhibitormouse modelneuroprotectionnew therapeutic targetnovelpre-clinicalresiliencescaffoldscreeningsmall moleculetargeted treatment
项目摘要
Abstract. Alzheimer’s disease (AD) affects more than 5M Americans today, and is the most common cause of
dementia in adults. While current medications slightly delay symptoms, no medications exist to cure or stop
disease progression. A current focus at NIA is to identify novel drug targets, that address resilience to AD; also,
there is an increasing perspective at NIA that Multi-target therapy may be necessary to overcome AD. We present
the novel drug target Shc, which was recently shown to be a major resilience factor in conversion from human
MCI to AD1, and whose activity rises in AD hippocampus2. Also, PSAPP mice with genetically decreased Shc
protein had increased cognitive function and memory and survival, with the same burden of plaques and tangles--
thus Shc reduction represents a novel target whose reduction enables a neuroprotective 'resilience' mechanism3.
Mice with genetic Shc deficiency are also protected from age related cerebrovascular dysfunction4 ALS5 and MS6,
so reduction of Shc activity increases neuroprotection and resilience in multiple neurodegenerative conditions. To
try to mimic the demonstrated neuroprotective benefit of genetic Shc reduction with a small molecule, we started
with a repurposing approach to isolate 6 chemical scaffolds with Shc blocking activity7. Then a novel 3-
dimensional scaffold search was carried out to identify 400 new molecules on completely novel scaffolds. These
400 have been winnowed down to a flock of 40 molecules through screening paradigms described in the
application and tested them in 20 HTS assays to confer neural cell resistance to amyloid beta and picked the 5
most neuroprotective. PK experiments on the 2 most neuro-protective revealed a better brain penetrance of one
molecule. Thus Buto's Aims are (1) to identify the Maximum Tolerated Dose (MTD) of this molecule, 2) to
determine Brain and Blood PBMC target engagement in a mouse model of oxidative stress, and 3) to determine
efficacy in the 5XFAD and ApoE4 mouse model. These Aims, once achieved, will determine the extent to which
molecules that hit a completely novel and never-drugged AD target Shc, are acceptable pre-clinical
pharmacological candidates, and set the stage for further partnering of Shc inhibitors in this indication.
抽象的。阿尔茨海默病(AD)影响今天超过500万美国人,是最常见的原因,
成人痴呆症虽然目前的药物稍微延迟症状,没有药物存在治愈或停止
疾病进展。NIA目前的重点是确定新的药物靶点,解决AD的弹性问题;此外,
在NIA,多靶点治疗对于克服AD可能是必要的,这一观点越来越多。我们提出
该新药靶向Shc,其最近被证明是从人类转化中的主要弹性因子
MCI至AD 1,AD 2组活性升高。此外,遗传性Shc降低的PSAPP小鼠
蛋白质增加了认知功能、记忆力和存活率,但斑块和缠结的负担相同--
因此,Shc的减少代表了一种新的靶点,其减少能够实现神经保护性的“恢复”机制3。
具有遗传性Shc缺陷的小鼠也被保护免于年龄相关的脑血管功能障碍4 ALS 5和MS 6,
因此,在多种神经退行性疾病中,Shc活性的降低增加了神经保护和恢复能力。到
为了用一种小分子来模拟遗传性Shc减少的神经保护作用,我们开始
用再利用方法分离6种具有Shc阻断活性的化学支架7。一本小说3-
进行三维支架搜索以鉴定在完全新颖的支架上的400个新分子。这些
400个分子已经通过文献中描述的筛选范例被筛选到40个分子的群体。
应用程序,并在20个HTS测定中测试它们,以赋予神经细胞对淀粉样蛋白β的抗性,并挑选了5个
最能保护神经对两种最具神经保护作用的药物进行PK实验,结果显示,
分子。因此,Buto的目的是(1)确定该分子的最大耐受剂量(MTD),2)
确定氧化应激小鼠模型中的脑和血液PBMC靶结合,以及3)确定
在5XFAD和ApoE 4小鼠模型中的有效性。这些目标一旦实现,将决定
分子击中一个完全新的和从未药物AD目标Shc,是可接受的临床前
药理学候选物,并为Shc抑制剂在该适应症中的进一步合作奠定基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gino A Cortopassi其他文献
Méthodes de traitement de maladies mitochondriales
疾病线粒体性状测定方法
- DOI:
- 发表时间:
2016 - 期刊:
- 影响因子:0
- 作者:
Gino A Cortopassi;Sandip K. Datta;Alfred Yu - 通讯作者:
Alfred Yu
Gino A Cortopassi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gino A Cortopassi', 18)}}的其他基金
Mitochondrial-mediated Lung Injury mechanisms of QACs in vivo
QACs 体内线粒体介导的肺损伤机制
- 批准号:
10675747 - 财政年份:2022
- 资助金额:
$ 32.94万 - 项目类别:
Mitochondrial-mediated Lung Injury mechanisms of QACs in vivo
QACs 体内线粒体介导的肺损伤机制
- 批准号:
10467271 - 财政年份:2022
- 资助金额:
$ 32.94万 - 项目类别:
'Novel Shc Blockers as potential Alzheimer's Disease Therapeutics
“新型 Shc 阻滞剂作为潜在的阿尔茨海默病治疗药物
- 批准号:
10395302 - 财政年份:2021
- 资助金额:
$ 32.94万 - 项目类别:
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease
研究酮症治疗的靶标、机制和最佳给药方式,以实现功能性长寿和阿尔茨海默氏病的治疗
- 批准号:
10203670 - 财政年份:2019
- 资助金额:
$ 32.94万 - 项目类别:
Friedreich's ataxia, mitochondrial biogenesis, and neurodegeneration
弗里德赖希共济失调、线粒体生物发生和神经变性
- 批准号:
9765713 - 财政年份:2019
- 资助金额:
$ 32.94万 - 项目类别:
Targeting Shc to reduce inflammation and fibrosis in the aging liver
以 Shc 为靶点,减少衰老肝脏的炎症和纤维化
- 批准号:
10436913 - 财政年份:2019
- 资助金额:
$ 32.94万 - 项目类别:
Elucidating biomarkers and mechanisms of the Ketogenic longevity mechanism
阐明生酮长寿机制的生物标志物和机制
- 批准号:
10398862 - 财政年份:2019
- 资助金额:
$ 32.94万 - 项目类别:
Elucidating biomarkers and mechanisms of the Ketogenic longevity mechanism
阐明生酮长寿机制的生物标志物和机制
- 批准号:
10685456 - 财政年份:2019
- 资助金额:
$ 32.94万 - 项目类别:
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease
研究酮症治疗的靶标、机制和最佳给药方式,以实现功能性长寿和阿尔茨海默氏病的治疗
- 批准号:
10685449 - 财政年份:2019
- 资助金额:
$ 32.94万 - 项目类别:
Investigations of targets, mechanisms, and optimal delivery of therapeutic ketosis for functional longevity and treatment of Alzheimer's disease
研究酮症治疗的靶标、机制和最佳给药方式,以实现功能性长寿和阿尔茨海默氏病的治疗
- 批准号:
10153620 - 财政年份:2019
- 资助金额:
$ 32.94万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 32.94万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 32.94万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 32.94万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 32.94万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 32.94万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 32.94万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 32.94万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 32.94万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 32.94万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 32.94万 - 项目类别:
Research Grant